XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2

SEGMENT INFORMATION (Tables)

9 Months Ended

Jul. 31, 2023

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

 SCHEDULE OF SEGMENT INFORMATION

		2023				2022				2023				2022
		For the Three Months Ended July 31,								For the Nine Months Ended July 31,
		2023				2022				2023				2022
Net Loss:
CAR-T Therapeutics		$	(1,091	)		$	(965	)		$	(2,999	)		$	(3,975	)
Cancer Vaccines			(1,390	)			(903	)			(3,261	)			(3,684	)
Anti-Viral Therapeutics			(62	)			(904	)			(960	)			(2,565	)
Other			(5	)			(3	)			11				(18	)
Total		$	(2,548	)		$	(2,775	)		$	(7,209	)		$	(10,242	)
Total operating costs and expenses		$	2,844			$	2,797			$	8,170			$	10,266
Less non-cash share-based compensation			(1,217	)			(1,446	)			(3,507	)			(5,546	)
Operating costs and expenses excluding non-cash share-based compensation		$	1,627			$	1,351			$	4,663			$	4,720
Operating costs and expenses excluding non-cash share-based compensation:
CAR-T Therapeutics		$	713			$	421			$	1,930			$	1,823
Cancer Vaccines			855				376				1,966				1,571
Anti-Viral Therapeutics			55				552				572				1,312
Other			4				2				195				14
Total		$	1,627			$	1,351			$	4,663			$	4,720

		July 31, 2023				October 31, 2022
Total assets:
CAR-T Therapeutics		$	11,640			$	16,921
Cancer Vaccines			13,968				9,442
Anti-Viral Therapeutics			898				3,811
Other			72				238
Total		$	26,578			$	30,412

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration